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Abstract
Background: Heparan sulfate glycosaminoglycans are diverse components of certain proteoglycans and are known
to interact with growth factors as a co-receptor necessary to induce signalling and growth factor activity. In this
report we characterize heterogeneously glycosylated recombinant human perlecan domain 1 (HSPG2 abbreviated
as rhPln.D1) synthesized in either HEK 293 cells or HUVECs by transient gene delivery using either adenoviral or
expression plasmid technology.
Results: By SDS-PAGE analysis following anion exchange chromatography, the recombinant proteoglycans
appeared to possess glycosaminoglycan chains ranging, in total, from 6 kDa to >90 kDa per recombinant.
Immunoblot analysis of enzyme-digested high Mr rhPln.D1 demonstrated that the rhPln.D1 was synthesized as
either a chondroitin sulfate or heparan sulfate proteoglycan, in an approximately 2:1 ratio, with negligible hybrids.
Secondary structure analysis suggested helices and sheets in both recombinant species. rhPln.D1 demonstrated
binding to rhFGF-2 with an apparent kD of 2 ± 0.2 nM with almost complete susceptibility to digestion by
heparinase III in ligand blot analysis but not to chondroitinase digestion. Additionally, we demonstrate HS-
mediated binding of both rhPln.D1 species to several other GFs. Finally, we corroborate the augmentation of FGF-
mediated cell activation by rhPln.D1 and demonstrate mitogenic signalling through the FGFR1c receptor.
Conclusions: With importance especially to the emerging field of DNA-based therapeutics, we have shown here
that proteoglycan synthesis, in different cell lines where GAG profiles typically differ, can be directed by
recombinant technology to produce populations of bioactive recombinants with highly similar GAG profiles.
Background
Heparan sulfate glycosaminoglycans (GAGs) that dec-
orate proteoglycan core proteins vary in chain length,
net charge, and charge distribution, making them quite
heterogenous. This is due, in large part, to post-transla-
tional addition, then removal, of sulfate groups to var-
ious positions on the constituent monosaccharides,
orchestrated by a battery of enzymes in a tissue- or cell-
specific manner [1]. This level of complexity and
potential regulation afforded by the proteoglycan system
can, therefore, be considered relatively high.
The GAG heparan sulfate has an important role in reg-
ulating cell function by serving as a co-factor, or co-
receptor, in growth-factor (GF) interactions. Indeed,
without available heparan sulfate proteoglycans (HSPGs),
growth factor activity would be limited; during develop-
ment, heparan sulfate (HS) deficiency is lethal [2] while
targeted disruption of normal HS post translational mod-
ification results in a structurally altered HS and lethality,
with kidney, lung, and skeletal defects [3,4].
The most highly studied and well-understood of the
interactions between HSPGs and GFs is that between
heparan sulfate and fibroblast growth factors 1 and 2
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(FGF-1, FGF-2), two closely related members of a large
FGF family [5]. FGFs are mitogenic for a variety of cell
types, promoting differentiation and wound healing [6].
The crystal structure of the ligand/receptor complex for
FGF-2 and the FGF receptor (PDB 1FQ9) has been deter-
mined, clarifying the importance of heparin (or heparan
sulfate) as a co-receptor in dimerization of the growth
factors and their receptors leading to activation [7].
Native perlecan (HSPG2, abbreviated here as Pln) is
an extracellular matrix proteoglycan with three HS side
chains linked to a large core protein of approximately
450 kDa in 5 recognizable domains which, themselves,
are comprised of subdomains [8,9]. Domain 1 of perle-
can (Pln.D1) comprises only a small fraction of the
native perlecan encoding an approximately 21 kDa pro-
tein core with the primary sequence potential for three
O-linked GAG chains. While the C-terminus of Pln.D1
is known to have sequence homology with an SEA mod-
ule that is also found in a related HSPG, agrin, and in
regions of other biomolecules receiving extensive O-
linked glycosylation [10], the tertiary structure of Pln.D1
is not known.
The HS of Pln.D1 is reported to promote cell adhe-
sion [11-14], to promote proliferation and/or differentia-
tion [15], and to bind and deliver growth factors
[11,16-19]. Independently, there is strong scientific sup-
port and rationale for a role of perlecan in angiogenesis
or neovascularization [17,20,21]. Interference between
FGF or VEGF and perlecan HS binding has been shown
to diminish the functional activity of these GF’s [6,22].
Numerous growth factors are being tested as thera-
peutic agents [23-29] and some are currently commer-
cially available. It is reasonable, therefore, that increased
levels of soluble HS proteoglycan delivered concomi-
tantly with certain growth factors would lead to
enhanced growth factor activity in a physiological man-
ner and be of value in wound management and healing.
While recombinant mouse [30] and human [31-33]
perlecan D1 have been partially characterized, here we
provide characterization of two human Pln.D1 recombi-
nants generated from adenovirus or plasmid DNA
expression.
Methods
Construction of Pln.D1 transgene
Perlecan D1 (Pln.D1) was cloned by reverse-transcrip-
tase extension of total human endothelial cell RNA
using perlecan specific primers, then amplified by PCR
and cloned into pcDNA 3.3+ (Invitrogen) incorporating
amino acids 1-198 or 1-247 (to include the region
between domains 1 and 2 up to and including the first
amino acid of domain 2). In each clone a Kozac-like
sequence (ccacc) was strengthened by inserting cca
immediately 5’ to the native ccatg at -2 relative to the
start codon (atg). The native secretory leader sequence
was not modified. A 6×-His tag was added to the C-ter-
minus of each clone for identification. Sequence identity
of the full-length domain 1 clone compared to the
HSPG2 (reference NP_005520.4) was confirmed. DNA
stocks were prepared with Qiagen endonuclease free
MaxiPrep kits.
Construction of Pln.D1 adenovirus
Pln.198 or Pln.247 transgenes were subsequently cloned
into an adenoviral expression construct with a CMV-5
promoter (Adenovator, Qbiogene). Adenovirus with a
Pln.D1 transgene (Pln.198-Ad and Pln.247-Ad) were iso-
lated using a ViraKit AdenoMini-24 system (ViraPur).
Synthesis of rhPln.D1
Hek 293 cells were grown on 100 mm culture dishes in
Dulbecco’s Modified Eagles Medium (DMEM, Sigma
Chemical Co.) with 44 mM NaHCO3, pH 7.2, and sup-
plemented with 10% (v/v) fetal bovine serum (FBS), 100
U/ml penicillin and 0.1 mg/ml streptomycin (Pen/Strep)
at 37°C with 5% CO2 in a humidified incubation cham-
ber. HEK 293 cells were cultured to 90% confluence then
transfected with lipoplexes containing Pln.198-pcDNA3.3
+ or Pln.247-pcDNA3.3+ and lipofectamine2000 (LF2K,
Life Technologies) in 1:1.5 or 1:2 μg DNA: μg LF2K stan-
dard ratio and following the manufacturer’s instructions
in the presence of serum. Cells were incubated for 3 days
following transfection and conditioned media containing
secreted protein was collected.
Alternatively, HEK 293 cells cultured to 90% con-
fluency were infected with Pln.198-Ad or Pln.247-Ad at
TCID50 1 × 107/ml and incubated for 5 days to express
protein.
Conditioned media containing secreted protein
synthesized by either method was collected and sepa-
rated from cellular debris by centrifugation for 10 min
at 5K rpm and 4°C and then filtered through a 0.2 μm
filter prior to anionic exchange chromatography.
Purification of high Mr rhPln.D1
Filtered media was diluted 10× into Binding Buffer (con-
taining 20 mM Tris, 62.5 mM NaCl, 0.25% Tween-20,
15 mM sodium azide, pH 8.0) and bound to a Hitrap
anion exchange column (Amersham) connected to an
AktaPrime FPLC at 5 ml/min. The column was washed
to a flat baseline, without Tween-20, and bound con-
taminants were removed by a continual wash with 10%
Elution Buffer (20 mM Tris, 1 M NaCl, 15 mM sodium
azide, pH 8.0) until a flat baseline was reached. Remain-
ing bound rhPln.D1 was eluted from the column with a
50 ml gradient to 100% Elution Buffer at 2.5 ml/min
collecting 1 ml fractions and monitoring absorbance at
280 nm.
Ellis et al. BMC Biotechnology 2010, 10:66
http://www.biomedcentral.com/1472-6750/10/66
Page 2 of 12
Analyzing the fractions by techniques described below,
fractions containing the high molecular weight (Mr), gly-
cosylated protein were pooled and the buffer was
exchanged to 50 mM HEPES, 250 mM NaCl, pH 8.0 by
repeated dilution and concentration using 6 ml centri-
cones (Vivascience, Sartouris Stedim) with 10 kDa
MWCO. After anionic exchange chromatography and
pooling of heterogeneous fractions, enriched high Mr
rhPln.247 from 100 ml conditioned medium generated
by adenovirus yielded 25 ml of 140 μg/ml protein as
determined by Abs280 using a calculated extinction coef-
ficient of 28795 M-1cm-1 for the recombinant. Enriched
high Mr rhPln.198 from 100 ml conditioned medium
yielded 10 ml of 140 ug/ml as determined by Abs280
and a calculated extinction coefficient of 25440 M-1 cm-
1. Plasmid transfection generated approximately 3 fold
less recombinant than adenoviral infection, per volume
conditioned media. For storage, 1% glycerol was added
to the protein stock and protein was stored at -20°C.
Western blot
Proteins were separated on a 12% SDS-PAGE gel at
200 V and transferred to nitrocellulose utilizing a
BioRad Mini Transblot system at 0.3 Amp for 90 mins.
The blot was blocked in 1.3 mM KCl, 0.8 mM KH2PO4,
68 mM NaCl, and 4.1 mM Na2HPO4 (PBS) containing
15 mM sodium azide and 0.1% Tween 20 (PBS-Tween)
for 30 min at room temperature and with agitation. The
blot was then incubated in primary antibody CSI 001-71
(Assay Designs, clone A71) overnight at 4°C with rock-
ing, washed in PBS-Tween, and incubated in goat-anti-
mouse AP conjugated secondary antibody (Abcam) for
2 hr at 4°C with rocking. After washing, the blot was
developed with SigmaFast BCIP/NBT tablets dissolved
in ddH2O and imaged on a Kodak GelLogic 1500 Ima-
ging System.
Stains-All/Silver
Acidic and/or glycosylated Pln.D1 was visualized by
SDS-PAGE and Stains-All staining enhanced by silver
nitrate similar to the protocols of Goldberg and Warner
[34]. Proteins were separated on a 12% SDS-PAGE gel,
and the gel was washed for 30 mins in 100 ml of 25%
isopropanol with 5 solution changes to remove the SDS.
The gel was then incubated in 30 ml of Stains-All stain-
ing solution (0.025% Stains-All in 30 mM Tris, 7.5% for-
mamide, 25% isopropanol, pH 8.0 from a stock of 0.25%
Stains-All in formamide) overnight in a light-tight box
at room temperature with agitation. The stain was
removed, and the gel was destained in 100 ml of 25%
isopropanol maintaining light tightness until the back-
ground was a light pink and protein bands could be dis-
cerned. The gel was imaged on a Kodak GelLogic 1500
with transmitted white light for 2.4 ms exposure with an
f-stop of 5.6. After imaging, the gel was allowed to fade
by light in 25% isopropanol intermittently exchanged
with ddH2O to a clear background. The gel was then
washed thrice with ddH2O and incubated in 60 ml of
freshly prepared 12 mM AgNO3 for 30 mins, rinsed
three times in ddH2O, and developed with 70 ml of 0.28
M Na2HCO3, 0.15% formaldehyde after rinsing the gel
twice quickly with approximately 15 ml of the same
solution. The development reaction was stopped with
10% acetic acid. The gel was again imaged using the
GelLogic 1500.
ELISA
Enzyme linked immunosorbant assays (ELISA) were per-
formed in polystyrene microtiter wells. Proteins were
coated overnight at 4°C onto the surfaces in PBS and 15
mM sodium azide (PBS-N
3
). All wells were then blocked
and washed in PBS-Tween. Primary murine antibodies
were applied in PBS-Tween at a concentration of 0.5
μg/ml overnight at 4°C. Secondary goat anti-mouse anti-
bodies conjugated with alkaline phosphatase (Abcam)
were applied at a concentration of 1 μg/ml for 2 h then
AP activity was monitored at 405 nm by hydrolysis of
the substrate 4-Nitrophenylphosphate (Boehringer Man-
nheim, Germany) in 10 mM Tris, pH 9.5 with 5 mM
MgCl2 using a Bio-Tek Instruments, Inc. μQuant spec-
trophotometer (absorbance maximum of 3.0 ELISA
units). Apparent dissociation constants (kD) were
derived by solid-phase with ELISA as previously
described [35] and presented with standard deviation.
Mass spectrometry analysis
MALDI-TOF mass spectrometry was performed after
tryptic digestion of rhPln.198 and rhPln.247 purified
protein. Enzymatic digestion with trypsin (12.5 ng/μl)
(Promega Gold Trypsin Mass Spectrometry Grade) was
carried out for sixteen hours at 37°C. Peptide solutions
were then extracted using two washes of 100 μl of a 50/
50 solution of 5% formic acid and acetonitrile for thirty
minutes. Supernatants were collected and dried down in
a Savant SpeedVac. Samples were resuspended in 40 μl
of 0.1% formic acid. C18 ZipTips (Millipore) were used
to desalt peptide mixtures before analysis. An aliquot
(5-10 μl) of each digest was loaded onto a 5 mm × 100
μm i.d. C18 reverse-phase cartridge at 2 μl/min. After
washing the cartridge for 5 min with 0.1% formic acid
in ddH20, the bound peptides were flushed onto a 22 cm
× 100 μm i.d. C18 reverse-phase analytical column with
a 25 min linear 5-50% acetonitrile gradient in 0.1% for-
mic acid at 500 nl/min. The column was washed with
90% acetonitrile-0.1% formic acid for 15 min and then
re-equilibrated with 5% acetonitrile-0.1% formic acid for
24 min. The eluted peptides were passed directly from
the tip into a modified MicroIonSpray interface of an
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Applied Biosystems-MDS-Sciex (Concorde, Ontario,
Canada) 4000 Qtrap mass spectrometer. Eluted peptides
were subjected to a survey MS scan to determine the
top three most intense ions. A second scan (the
enhanced resolution scan) determined the charge state
of the selected ions. Finally, enhanced product ion scans
were carried out to obtain the tandem mass spectrum of
the selected parent ions (with the declustering potential
raised to 100 V) over the range from m/z 400-1500.
Spectra were centroided and de-isotoped by Analyst
Software, version 1.42 (Applied Biosystems). These tan-
dem mass spectrometry data were processed to provide
protein identifications using an in-house MASCOT
search engine (Matrix Science) against the NCBInr
Human Protein database.
Circular dichroism of rhPln.D1
CD was performed on 5.6 μM rhPln.198 or 8.4 μM
rhPln.247 in 25 mM HEPES, 100 mM NaCl, pH 7.4
using a Jasco J-815 spectrometer at 20°C, 0.5 mm path-
length cell, 4 accumulations, 1 nm steps, and from 240
to 190 nm. Buffer was the baseline and was subtracted
from the protein spectrum. All spectra were computa-
tionally smoothed and filtered (FFT) with the Jasco
Spectra Analysis software. Estimations of helix and
strand content were calculated with Raussens method
http://perry.freeshell.org/raussens.html.
Growth factor ligand blot
rhPln.D1 samples were separated on a 12% polyacryla-
mide gel and transferred to nitrocellulose for 1.5 hr at
0.3 Amp. After blocking, blots were incubated in 0.1 μg/
ml rhFGF-2 (R&D Systems) in PBS-Tween overnight at
4°C with rocking. Blots were washed in PBS-Tween and
incubated in 1 μg/ml anti-FGF-biotin antibody (R&D
Systems) for 4 hr at 4°C with rocking, then washed in
PBS-Tween, and incubated in 1 μg/ml streptavidin-alka-
line phosphatase (R&D Systems) for 2 hr at 4°C with
rocking. Blots were then developed and imaged as
described in the section Western blots above.
Glycosidase digestion
Enriched Pln.D1 was digested with heparinase I, II
(Sigma or IBEX Technologies), and III (Seikagaku) and
with chondroitinase ABC (Seikagaku) overnight at 37°C
with 1 mU of enzyme/μg Pln.D1 in 50 mM HEPES, 200
mM NaCl, pH 7.4. Controls of undigested protein were
also incubated in the same manner. Digested samples
were examined by mAb 001-71 Western blot and Stains-
All/Silver SDS-PAGE applying 2.8 μg protein/lane.
Ligand binding ELISA
The ligand binding assay was a variant of the ELISA in
which dilutions of ligand (rhFGF-2) were allowed to
bind to a ligand binding protein such as rhPln.D1 that
had been coated onto the wells in PBS-N3. The bound
ligand was then detected with biotin-conjugated mAb
specific for hFGF-2 which was followed by a streptavi-
din-AP conjugate and developed as described for ELISA.
Apparent kD were derived as previously described [35]
in these assays using serial dilutions of ligand with even
amounts of coated ligand binding protein. Results are
accompanied by standard deviation.
Growth factor dot blots
Growth factors rhFGF-2, rhVEGF165, rhVEGF189,
rhPDGF-BB, rhEGF, rhIGF, rhFGF-7, rhBMP-2, rhBMP-
6, rhBMP-7, rhBMP-9, and rhBMP-14 were bound to
nitrocellulose at 500 ng utilizing a BioRad dot blot appa-
ratus. Blots were blocked in PBS-Tween and incubated
in 1 μg/ml rhPln.198 or rhPln.247 (separate blots) in
PBS-Tween overnight at 4°C with rocking. Alternatively,
some blots were incubated in heparinise III digested
rhPln.247 (also 1 μg/ml) overnight at 4°C with rocking.
After washing, blots were incubated in 3 ug/ml rhPln.
D1 primary antibody CSI 001-71 in PBS-Tween over-
night at 4°C with rocking. Blots were then washed and
incubated in 1 ug/ml goat-anti-mouse AP conjugated
secondary antibody for 2 hr at 4°C with rocking. Blots
were then developed and imaged as described.
Baf32 proliferation assays
Proliferation of FGFR1c-expressing Baf32 cells were
monitored via MTS reagent and absorbance at 490 nm
with the addition of 0.3 nM rhFGF-2 and titration of
rhPln.247. Baf32 cells were maintained in RPMI 1640
medium containing 10% v/v FBS, 10% v/v WEHI-3BD
conditioned medium and 1% v/v penicillin/streptomycin.
For the mitogenic assays, the Baf32 cells were trans-
ferred into IL-3 depleted medium in low serum for 24 h
prior to experimentation and seeded into 96-well plates
at a density of 2 × 104 cells/well in the presence of
FGF-2 (0.03 nM), heparin (30 nM) and either HCAEC
perlecan (2 μg/ml) or rhPln.247 (1-20 μg/ml). Cells were
incubated for 96 h in 5% CO2 at 37°C and the amount
of cells present was assessed using the MTS reagent
(Promega, Madison, Wisconsin, USA) by adding to the
cell cultures for 6 h prior to measuring the absorbance
at 490 nm.
HUVEC proliferation assays
HUVEC were purchased from Lifeline Cell Technolo-
gies, Inc. and cultured according to the manufacturer’s
instructions with LCT VascuLife EnGS medium includ-
ing all supplied LifeFactors (2% serum, L-glutamine,
Hydrocortisone, Heparin, Ascorbic acid, EGF, EnGs).
For proliferation studies, low passage number cells
(below P14) were seeded in 96 well plates directly into
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experimental medium at 104 cells/well in 200 μl Assay
Medium, LCT VascuLife EnGs containing only selected
LifeFactors (2% serum, L-glutamine, Hydrocortisone,
EnGS). Experimental conditions included 5 ng/ml of
growth factor (rhFGF-2, R&D Systems) in Assay Med-
ium with dilutions of enriched rhPln.198 or rhPln.247.
Cell count was measured after 48 hr incubation by con-
version of Dojindo’s CCK8 dye with 1 hr incubation on
live cells. Resulting absorbance of the converted sub-
strate was measured at 450 nm in a parallel microtiter
plate. Measurements were adjusted for background with
measurements taken from control media.
Results
Anion exchange chromatographic separation of rhPln.D1
by GAG level
HEK 293 cells were infected with the Pln.247-Ad or the
Pln.198-Ad and the conditioned medium was subjected
to anion exchange chromatography with a linear NaCl
gradient to 1 M (Figure 1A). Testing the hypothesis that
retention on the anionic exchange column through
increasing ionic strength of the elution buffer would be
characterized by an immunopositive rhPln.D1 with
increasing GAG chain length, we sampled a broad range
of immunopositive fractions by Western blot using the
anti-Pln.D1 mAb CSI 001-071 (Figure 1B,C). In the
eluant, we found that the immunoreactive species with
the lower net apparent kDa (shorter GAGs) eluted ear-
liest (up to 26 ml) and that increasing salt eluted rhPln.
D1 species with increasing GAG length and greater
apparent kDa. The early fractions of each recombinant
were characterized by highly immunoreactive, minimally
glycosylated species, the lowest approximately where the
unglycosylated core of Pln.198 (Figure 1B) and Pln.247
(Figure 1C) was expected to migrate. Beyond 30 ml,
eluting from approximately 0.5 M NaCl, these lower Mr
species were absent while a broad range of immunoreac-
tivity spanning 30-60 kDa upward (Pln.198) or 50-120
(Pln.247) eluted, gradually increasing in apparent Mr
through 52 ml (eluting in 1 M NaCl). The range of
apparent kDa in these higher Mr fractions suggested a
recombinant species with GAG chains totalling 24 kDa
to >90 kDa in rhPln.247, or average individual chain
sizes of 8-30 kDa, assuming glycosylation of the 3 SGD
linkage sites within rhPln.247. The higher Mr fractions
of Pln.198 did not appear to be glycosylated as exten-
sively, with estimated GAG chains of 3-13 kDa again
assuming glycosylation at each of the three SGD regions
in rhPln.198. The synthesis of rhPln.247 in HUVEC cul-
ture resulted in matching data (Figure 1F, Western
blot). Similar data were also produced when the HEK
293 cells were transfected instead with a mammalian
expression plasmid encoding the Pln.247 transgene (data
not shown).
While it appeared by immunoblot with mAb 001-71
that the overwhelming majority of both rhPln.198 and
rhPln.247 were poorly glycosylated, the use of protein
staining in companion Stains-All gels (Figure 1D,E) or
silver stain (not shown) demonstrated that the more
extensively glycosylated species constituted the majority
of recombinant in the eluant, suggesting that the CSI
001-71 mAb had been more reactive with rhPln.D1 spe-
cies having undeveloped or shortened GAG chains.
Native Pln not detected in high Mr rhPln.D1 preparation
To support the hypothesis that the CSI-001-71 immu-
noreactive species eluting in relatively high salt were
recombinant and not native Pln.D1, we pooled the frac-
tions from 34-52 ml containing only high Mr rhPln.D1,
reduced the salt by buffer exchange, then aliquots were
immobilized in microtiter wells and ELISA performed
with a panel of anti-perlecan antibodies (Figure 2).
These data indicated that the perlecan core was recog-
nized only by the anti-D1 core antibody CSI 001-71 but
not by the anti-D3 antibody 7B5 (Invitrogen cat. 13-
4400) nor the anti-D4 antibody A7L6 (Millipore
mAb1948) nor the anti-D5 antibody CSI 001-74. The
recombinant pools were each found to have CS glycosy-
lation recognized by mAb CS56 (Sigma Aldrich) while
mAb 10E4 recognized the predominately unsulfated HS
epitopes [36]. Interestingly, mAb CSI 001-76 (clone
A76), that is known to recognize domain 1 of native
perlecan (Figure 2 inset, endothelial perlecan), poorly
recognized the truncated recombinants rhPln.198 (Fig-
ure 2) and rhPln.247 (inset, Figure 2) relative to mAb
CSI 001-71 (A71).
Mass spectrometry analysis of trypsin-digested puri-
fied rhPln.198 resulted in the identification of several
Pln.D1 fragments (Figure 3) but no other perlecan
domains were detected. However, analysis of western
blots with gels developed with silver or Stains-All sug-
gested that the higher Mr fractions selected for pooling
and analysis had minor levels of contaminating pro-
teins (Figure 1). By mass spectrometry of enriched
rhPln.198 or rhPln.247, only three other minor protein
contaminants were identified, presumably from the use
of fetal bovine serum in the growth medium: bovine
lumican, bovine hemoglobin, and BSA (data not
shown).
Circular dichroism
The CD spectra of the Pln.198 and Pln.247 differ slightly
(Figure 4), likely due to the probable cysteine knot
structure at the C-terminus of Pln.247. Analysis of the
spectra by Raussens method predicts Pln.198 to be
35.2% helical, 19.1% strand, 31.8% coil, and 12.5% turn,
and Pln.247 to be 27.5% helix, 23.7% strand, 34.3% ran-
dom coil, and 12.5% turn.
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Figure 1 Anion Exchange Chromatography of rhPln.247 conditioned media (CM). A: Chromatogram of elution profile for rhPln.198-Ad and
rhPln.247-Ad CM expressed from HEK 293 cells; B and C: Western blots of anion exchange fractions with mAb CSI 001-71 recognizing the Pln.D1
core; D and E: Stains-All analysis of HEK 293 fractions; F: Fractions from HUVEC synthesis. Panels B and D represent rhPln.198 fractionation; panels
C, E, F represent rhPln.247 fractionation. (M) Markers; (CM) Conditioned medium undiluted from cells. Similar data were generated using plasmid
expression of pln.247 (not shown).
Ellis et al. BMC Biotechnology 2010, 10:66
http://www.biomedcentral.com/1472-6750/10/66
Page 6 of 12
CS and HS decorate rhPln.D1 but not together
To assess the relative contributions of CS and HS to
each of the recombinants, aliquots of the high Mr rhPln.
D1 preparations were digested with heparinases I, II, or
III, or with chondroitinase ABC, or with mammalian
heparanase (Figure 5). By western blot, treatment with
heparinase I or II produced no measurable change in
the staining pattern in either of the recombinant pools
(rhPln.198 from HEK 293 cells and rhPln.247 from
HUVEC). Treatment with heparinase III resulted in the
appearance of low Mr species similar to those seen early
in the elution profile (Figure 1). Treatment with chon-
droitinase ABC resulted in significant loss of the major
Pln.D1 immunoreactivity and a more dense low Mr
band. Treatment of the recombinant proteoglycans with
the combination of heparinases and chondroitinase ABC
resulted in further elimination of the higher Mr immu-
noreactivity, and greater density in the low Mr band.
Treatment with mammalian heparanase did not demon-
strate a clearly observable specific activity against the
Figure 2 ELISA identifies only Pln.D1 but not Pln.D3-5 in
enriched rhPln.198. The enriched high Mr rhPln.198 synthesized by
HEK 293 cells was used to coat microtiter wells that were
subsequently blocked then incubated with 1.7 μg/ml of different
primary antibodies as depicted in the legend. ELISA was completed
as described in Methods. Background signal for each antibody
binding to uncoated wells was subtracted to produce the net
signal. Inset: ELISA data showing negligible mAb A76 reactivity
against rhPln.247 and strong reactivity with full-length endothelial
perlecan (purified as previously described [53]), while mAb A71
reacted strongly to both the native perlecan and the truncated
recombinant. Net absorbance minus buffer-coated wells
represented.
Figure 3 Tryptic peptides of purified rhPln.198 by mass
spectrometry. Purified rhPln.198 was subjected to trypsin digest
and fragments were analyzed by mass spectrometry. Red underline
signifies fragments identified in this analysis of enriched rhPln.198.
Figure 4 Circular dichroism of 5.6 μM Pln.198 and 8.4 μM
Pln.247 in 25 mM HEPES, 100 mM NaCl, pH 7.4 with baseline
subtraction and FFT filter. The differences in the spectra suggest a
structural difference in the two proteins, likely due to the addition
of the 47 amino acids on Pln.247 that form a cysteine knot.
Figure 5 Western blots of rhPln.D1 glycosidase digests. Pooled
anionic exchange fractions (34-52 ml) from HEK 293 culture (Pln.198)
or HUVECs (Pln.247) were subjected to digestion with either buffer
only, heparinase I (Hep I), heparinase II (Hep II), heparinase III (Hep III),
chondroitinase ABC (Chond. abc), all three heparinases plus
chondroitinase ABC, or heparanase. Treated samples were analyzed
by western blot using mAb CSI 001-71. Similar data were generated
using plasmid expression of pln.247 (not shown).
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recombinant pools by this assay (Pln.247, Figure 5;
Pln.198, data not shown). In summary, data from these
experiments suggested that recombinant synthesis of
different Pln.D1 variants in these two different cell types
generated similar HS and CS levels. Also, it is important
to note that digestion with either heparinase III or
chondroitinase ABC did not produce intermediate bands
of immunoreactivity or silver staining between the high
Mr rhPln.D1 and the dominant digest products (43 kDa,
Pln.247; 33 kDa, Pln.198); this suggested that the core
proteins were either fully decorated with HS (approxi-
mately 1/3 of total) or fully decorated with CS (approxi-
mately 2/3 of total), and that there were negligible
hybrids.
FGF-2 binding is mediated by rhPln.D1 HS but not CS
Knowing that a significant proportion of the rhPln.198
and rhPln.247 was glycosylated with HS, we tested the
hypothesis that the rhPln.D1 would bind FGF-2. Apply-
ing rhFGF-2 in solution to the electrophoretically sepa-
rated recombinant pools that had been immobilized on
a nitrocellulose blot (Figure 6), the FGF-2 bound specifi-
cally to the rhPln.198 and rhPln.247. Further, digestion
with heparinase III, but not chondroitinase ABC, mostly
eliminated FGF binding to the enriched rhPln.D1 in this
system.
Solid phase binding analysis of rhFGF-2 to the
rhPln.198 and rhPln.247 demonstrated an estimated kD
of 2.0 ± 0.2 nM for each, which was similar to binding
of rhFGF-2 with a commercial HSPG (Sigma Aldrich)
(Figure 7). Binding was the same when capturing the
rhPln.D1 in the high Mr preparations onto a solid-phase
anti-perlecan mAb 001-71 ensuring that binding of
FGF-2 to the enriched high Mr Pln.D1 was a result of
binding to the rhPln.198 and not a contaminant (data
not shown).
rhPln.D1 HS mediates binding to several growth factors
Nitrocellulose immobilization of several growth factors
and immunoblot analysis confirmed binding of
rhPln.198 and rhPln.247 with the growth factors rhFGF-
2, rhBMP-6, rhBMP-7, rhPDGF-BB, and VEGF189 (Fig-
ure 8A). A significant reduction in binding signal for
each resulted from pre-treating the rhPln.D1 with
heparinase III (Figure 8B) suggesting some GF affinity
for HS. No binding with rhFGF-7 (Figure 8) or rhEGF,
rhIGF, BMP-9, and VEGF165 (not shown) was detected
by these methods. Results were similar using the
rhPln.198 (not shown).
Mitogenic activity of rhPln.247 and rhPln.198
A mitogenic dose response to rhPln.247 by HUVEC in
low-serum growth medium occurred (Figure 9A). Using
Baf32 cells, which have a limited mitogenic response to
growth factors and express only the FGFR1c receptor,
we demonstrated rhPln.247-dependant mitogenicity
through the FGF-2/FGFR1c activation pathway (Figure
9B). Similar results were obtained with rhPln.198 also
demonstrating a dose-dependent synergistic response of
HUVEC to rhPln.198 in the presence of constant
rhFGF-2 levels (Figure 9C).
Figure 6 FGF-2 ligand blot binding of glycosidase-digested
rhPln.D1. Pooled anionic exchange fractions of rhPln.198 or
rhPln.247 from HEK 293 cell culture were subjected to digestion as
designated; buffer only, heparinase I (Hep I), heparinase II (Hep II),
heparinase III (Hep III), chondroitinase ABC (Chond. abc), all three
heparinases plus chondroitinase ABC, or heparanase. Samples were
subjected to SDS-PAGE and blotted to nitrocellulose. After blocking,
the blot was then incubated with rhFGF-2 overnight, washed, then
the bound rhFGF-2 was detected by anti-FGF-2 biotin-conjugates
and streptavidin-alkaline phosphatase staining.
Figure 7 Growth-factor binding to rhPln.198, rhPln.247, and
HSPG in solid phase. Commercial HSPG, Pln.247, or rhPln.198 were
bound directly to polystyrene microtiter wells. The proteoglycan
samples were incubated with 6-fold dilutions of rhFGF-2. After
washing away unbound FGF, the bound FGF was detected with
anti-FGF biotin conjugates.
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Discussion
Graham et al had demonstrated that a human perlecan
domain 1 recombinant from HEK 293 cells was 67%
HS, but that a fusion of domain 1 with the large C-
terminal globular protein EGFP resulted in a 100% HS
recombinant, similar to what is typically found in the
native perlecan [31]. Also, Doege et al showed a predo-
minately HS decoration of recombinant Pln.D1 when
expressed with domains II and III in Cos-7 cells [37].
It appears, therefore, that structural changes to the C-
terminus of domain 1 of perlecan can have a qualita-
tive role in the post-translational glycosaminoglycan
decoration of the core, and it is all the more interest-
ing that the rhPln.198 and the rhPln.247, which are
different by 49 amino acids at the C-terminus, were
similar in their CS/HS ratio of approximately 2:1.
Further, by gel analysis of glycosidase-treated recombi-
nants (both rhPln.198 and rhPln.247) using both wes-
tern blot (Figure 5), silver stain and Stains-All (not
shown), recombinant was shown to be predominately
synthesized with either only HS glycosylation or only
CS glycosylation, but not with both, similar to the two
pools of rhPln.D1 previously demonstrated using the
mouse perlecan, one having only HS and the other
containing CS [30,38].
It is postulated that the action of two separate
enzymes dictates whether a beta-GalNAc or alpha-
GlcNAc linkage is formed following the linker tetrasac-
charide, hence initiating a CS or HS GAG, respectively
(reviewed in [39]). In our work, separate pools of homo-
genous GAG types may have derived from variable, or
more labile, tertiary structures of the truncated core
proteins that favored either HS or CS enzymatic initia-
tion. Alternatively, signals for specific HS or CS initia-
tion, possibly relating to differential transit through the
Golgi, were removed in truncation resulting in balanced
populations of HS or CS species initiated in either the
Golgi or trans-Golgi network, respectively [40]. Interest-
ingly, the relatively higher proportion of CS-Pln.D1 in
our enriched pools may be due to lower intravesicular
pH, where more acidic vesicles are more likely to result
in relatively less HS and relatively more CS [40].
Accordingly, the calculated pI of the rhPln.D1 is an
acidic 4.5 as compared to a pI of 6.5 for the full length
perlecan core.
These data demonstrated synthesis of recombinant
Pln.D1 with highly heterogenous GAG chains contribut-
ing approximately 6-90 kDa to the rhPln.D1 core, con-
sistent with the HS chain length previously estimated in
rhPln.D1 characterized elsewhere [31] but greater than
what had been estimated for recombinant mouse Pln.
D1, also expressed in HEK 293 cells [30] or in CHO K1
cells [38]. In anion exchange chromatography, we
hypothesized that recombinant Pln.D1 would elute pri-
marily by degree of sulfation, though what we found
was that the species with the lower net apparent kDa
(shorter GAGs) eluted earliest. With increasing salt
eluted rhPln.D1 species with increasing GAG length and
greater apparent kDa. This would also suggest an overall
similarity throughout each of the synthesized recombi-
nant populations with regard to net sulfation.
Not only does the primary sequence of Pln.D1 permit
both HS and CS [38], but the cell type in which Pln is
produced can influence the GAG composition; mixed
forms have been seen in EHS tumor cells [41], and glo-
merular epithelial cells [42]. Sulfation patterns on perle-
can can also vary significantly depending on the cell
type, and endothelial cells, including HUVEC, have pre-
viously been shown [43] to synthesize a perlecan with
relatively less FGF-2 binding activity than other cell
types, emphasizing the potential value of in situ post-
translational modification with the use of recombinant
biologics for therapy.
Typical interactions between FGF-2 and HS proteogly-
cans has been reported to range from kD = 0.5 nM for
syndecan-3 [44] to kD = 2 nM for the secondary phase
of binding to HUAEC perlecan [43], to kD = 15 nM for
HS recovered from mouse embryonic fibroblasts [45].
Our estimated kD of 2 ± 0.2 nM for FGF-2 binding to
Figure 8 Immunoblot analysis of growth factor binding to
Pln.198 and Pln.247. 500 ng growth factors were bound to
nitrocellulose, the blots were blocked, and then incubated in either
1 ug/ml Pln.198 or Pln.247 (panel A) or rhPln.247 pre-digested with
heparinase III (panel B). Detection was performed with anti-perlecan
domain 1 primary antibody CSI 001-71. Note that while both the
background BSA signal and the internal control rhPln.247 signals are
slightly higher in panel B (bottom two samples), a decrease in the
growth factor binding to Pln.247 was present after digestion.
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both rhPln.198 and rhPln.247 synthesized by HEK 293
cells was similar in magnitude and virtually identical to
the apparent net affinity of rhFGF-2 for a commercial
HSPG. These data support the hypothesis that the qual-
ity of the HS decorating the rhPln.198 and rhPln.247
are quite similar.
While CS of rhPln.D1 has been shown to bind rhFGF-
2 [33], in our system, chondroitinase ABC insignificantly
affected the rhPln.198 or rhPln.247 binding to FGF-2.
Our data suggested that HS participated in FGF-2 bind-
ing to the rhPln.D1 synthesized in HEK 293 cells while




Figure 9 Mitogenic Activity of rhPln.247 and rhPln.198. HUVEC (panel A, C) or Baf32 cells (panel B) demonstrated a dose-dependent
mitogenic response to rhPln.247 (panel A, B), or rhPln.198 (panel C). Panel B: Proliferation augmentation of FGFR1C expressing BAF32 cells by
Pln.247 in the presence of 0.3 nM rhFGF-2 (solid). No proliferation enhancement was observed with Pln.247 without FGF-2 (crosshatch). In panel
C, data represents the net absorbance for varying amounts of Pln.D1 with constant growth factor concentration after subtracting the
contribution from Pln.D1 alone (without growth factor). Data are the average of four experiments.
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similar to data reported for a pool of mouse Pln.D1 pro-
duced in a similar cell line [32]. Baf32 cells are an IL-3
dependent and HSPG deficient myeloid B cell line
which have been stably transfected with either FGFR1c
or FGFR3c [46,47]. The data presented here clearly
demonstrated a strong co-receptor activity of the
rhPln.247 with the rhFGF-2 signalling through the
FGFR1c. Interestingly, mitogenic dose dependence of
rhPln.247 in Baf32 cell culture supplemented with FGF-
2 was also in the presence of low-level heparin. While
the FGF-2/heparin combination provided no mitogenic
effect, the FGF-2/rhPln.D1 combination in the presence
of the heparin was highly mitogenic, highlighting the
functional difference between the recombinant HSPG
and heparin resulting from qualitative and quantitative
differences in sulfation.
There is good evidence that the HS proteoglycans
interact with several growth factors such as the VEGFs
and BMPs via the HS chains [48-51]. Data presented
support this potentially broad role of HS GAGs in med-
iating GF activities and support the possibility of
enhanced growth factor function in wound healing
through the use of recombinant HS proteoglycans.
Currently, no structural data exists for Pln.D1 and the
limited sequence identity of Pln.D1 with other known
structures causes difficulty in modelling of the full
domain. The SEA domain, approximately 90 amino
acids at the C-terminus of Pln.198, suggests a mixed a-
helix and b-sheet configuration. The CD data presented
for rhPln.198 and rhPln.247 confirm that hypothesis.
rhPln.247 spectral analysis demonstrated a difference
with rhPln.198 in the amount of helix vs. strand, which
may be due to the 47 additional amino acids forming a
C-terminal cysteine knot.
Assessment of the enriched recombinant pools using
two different antibodies known to recognize domain 1
of perlecan (CSI 001-A71 and -A76) provided additional
evidence that the proteoglycan pool was predominately
recombinant D1 without detectable native D1. Support
for this derives from published work showing mAb A76
to react relatively strongly with native perlecan D1,
while reacting very weakly with a Pln.196-EGFP C-term-
inal fusion protein [52]. Further support was obtained in
our labs with immunoblots demonstrating a significantly
reduced binding signal from the A76 mAb relative to
the A71 mAb for various rhPln.D1 species (not shown)
and ELISA data showing poor A76 reactivity against
rhPln.247 and strong reactivity with full-length endothe-
lial perlecan, while A71 reacted strongly to both the
native full-length perlecan and the truncated recombi-
nant (inset Figure 2). Therefore, contaminating levels of
native perlecan within the enriched recombinant pre-
parations would have also been detected with the A76
antibody, but were not.
Pln.D1 plasmid expression has been used to generate
relatively high levels of small, soluble, stable recombi-
nant HS proteoglycan. While the benefits of inserting an
alternative leader sequence have been described [31], we
found that use of the CMV promoter with the native
leader sequence had the potential for excellent expres-
sion of rhPln.198 and rhPln.247 from both the adeno-
viral and plasmid expressions systems, by both HEK
cells and HUVECs. While we did not test constructs
with the minimal native Kozak-like sequence for ribo-
some binding, we suspect that improvement of the
Kozak sequence also contributed to a relative high
expression level for these recombinant proteoglycan
constructs.
Conclusions
As more is presented and understood about proteoglycan
synthetic pathways and their controlling factors, the
applicability and usefulness of a secreted, functional,
soluble, relatively small-sized recombinant HS proteogly-
can should increase. With consistent synthesis and recov-
ery of a HS-decorated rhPln.D1 pool that has the
potential to bind and activate growth factors, the use of
Pln.D1 as a research tool and therapeutic adjunct for a
number of indications is possible and currently in testing.
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